Overview

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.
Phase:
PHASE4
Details
Lead Sponsor:
Mayo Clinic
Treatments:
cariprazine
Vortioxetine